Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $6.85M | $0.00 | $15.0M |
| Revenue growth | — | — | — | — | — | -100.0% | — |
| Operating income | -$5.05M | -$10.4M | -$374M | -$212M | -$171M | -$201M | -$208M |
| Operating margin | — | — | — | — | -2499.4% | — | -1384.6% |
| Net income | -$5.06M | -$10.7M | -$381M | -$216M | -$151M | -$236M | -$198M |
| Net margin | — | — | — | — | -2204.7% | — | -1316.9% |
| EPS (diluted) | — | — | -$5.07 | -$2.31 | -$1.57 | -$2.06 | -$1.46 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.83M | -$10.6M | -$135M | -$201M | -$160M | -$142M | -$194M |
| Capital expenditures | $0.00 | $0.00 | $186K | $1.14M | $169K | $34.0K | $371K |
| Free cash flow | -$5.83M | -$10.6M | -$135M | -$202M | -$161M | -$142M | -$194M |
| Share buybacks | $0.00 | $0.00 | $12.0K | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6M | $7.23M | $595M | $394M | $128M | $383M | $61.3M |
| Total assets | — | $11.7M | $630M | $444M | $360M | $577M | $687M |
| Total liabilities | — | $8.62M | $138M | $108M | $124M | $175M | $161M |
| Long-term debt | — | $0.00 | $75.7M | $69.8M | $75.7M | $109M | $110M |
| Shareholders' equity | — | — | $492M | $336M | $236M | $402M | $527M |
| Retained earnings | — | — | -$386M | -$602M | -$753M | -$989M | -$1.19B |
| Shares (wtd avg diluted) | — | — | 75.2M | 93.4M | 96.2M | 114M | 136M |
Every figure is extracted from Centessa Pharmaceuticals plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.